Findings

What do systematic reviews say?

2 questions · 2 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 50%Moderate 1 · 50%High 0 · 0%

Remdesivir and standard care vs placebo or usual care

Adverse events: all grades · non‐hospitalised adults with mild COVID‐19

Remdesivir and standard care showed no clear difference in adverse events (any grade) at up to day 28 compared with standard care (plus/minus placebo) (moderate certainty).

1 finding from 1 review

Remdesivir for the treatment of COVID‐19 2023 · Cochrane Headline outcomes only
RR 0.91 [0.76, 1.1]
1 study · 562 participants
Moderate

Remdesivir and standard care vs placebo or usual care

Adverse events: all grades · hospitalised individuals with COVID‐19 (moderate to severe disease)

Remdesivir and standard care showed no clear difference in adverse events (any grade) at up to day 28 compared with standard care (plus/minus placebo) (low certainty).

1 finding from 1 review

Remdesivir for the treatment of COVID‐19 2023 · Cochrane Headline outcomes only
RR 1.04 [0.92, 1.18]
4 studies · 2498 participants
Low